• In the past week, Artivion reported fourth-quarter 2025 results showing revenue of US$115.99 million and net income of US$2.43 million, marking a move from a loss a year earlier and contributing to full-year revenue of US$441.33 million and net income of US$9.77 million.
• At the same time, new clinical data from the NEXUS TRIOMPHE and AMDS PERSEVERE trials reinforced the performance of Artivion’s aortic arch therapies, which management now cites as central to its 2026 revenue guidance of US$486 million to US$504 million and expanding operating margins.
• We'll now examine how Artivion’s revenue miss but stronger full-year guidance and trial data affect its earlier growth-focused investment narrative.

Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

Artivion Investment Narrative Recap

To own Artivion, you need to believe its focused aortic arch portfolio and improving profitability can support ongoing double digit growth while it manages reimbursement, regulatory and balance sheet risks. The latest quarter’s revenue miss does not materially change the near term catalyst, which is U.S. approval and commercialization progress for AMDS and NEXUS, but it does keep execution risk in focus as the company leans on these products to meet its 2026 guidance.

The recent NEXUS TRIOMPHE and AMDS PERSEVERE trial updates matter here because they underpin management’s confidence in those aortic arch platforms and their role in the 2026 US$486 million to US$504 million revenue outlook. Strong one and two year clinical outcomes in high risk patients support Artivion’s effort to convert its trial and PMA work into higher margin product sales if regulatory timelines hold and hospitals maintain adoption.

Yet despite this progress, investors should still pay close attention to Artivion’s high debt load and the risk that...

Artivion's narrative projects $571.4 million revenue and $37.4 million earnings by 2028.

Uncover how Artivion's forecasts yield a $51.71 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span a wide range, from about US$16.22 to US$51.71 per share. With such different expectations in play, it is worth weighing how much of Artivion’s future depends on successful regulatory approvals and commercialization of AMDS and NEXUS before forming your own view.

Explore 2 other fair value estimates on Artivion - why the stock might be worth as much as 41% more than the current price!

Build Your Own Artivion Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Artivion research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Artivion research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Artivion's overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.